Activities of daily living in myotonic dystrophy type 1.
activities of daily living
quality of life
social participation
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
15
05
2019
revised:
11
12
2019
accepted:
27
12
2019
pubmed:
1
1
2020
medline:
25
8
2020
entrez:
1
1
2020
Statut:
ppublish
Résumé
The objective of this cross-sectional, observational study was to investigate performance of activities of daily living in patients with myotonic dystrophy type 1 (DM1). Adults with genetically confirmed DM1 were recruited from Newcastle University (Newcastle upon Tyne, UK) and University College London Hospitals NHS Foundation Trust (London, UK). Data on activities of daily living were recorded through the DM1-Activ Our sample comprised 192 patients with DM1 (mean age: 46 years; 51% female). Patients reported most difficulties with running, carrying and putting down heavy objects, and standing on one leg, and least difficulties with eating soup, washing upper body, and taking a shower. Irrespective of the disease duration (mean: 20 years), most patients were able to perform basic and instrumental activities of daily living (eg personal hygiene and grooming, showering, eating, cleaning and shopping), with the exception of functional mobility/transfer tasks (eg walking uphill and running). The mean DM1-Activ We show that DM1 impairs performance of activities of daily living, in particular those requiring a high degree of muscle strength, stability and coordination. Yet, across the evolution of the disease, the majority of patients will still be able to independently perform most basic and instrumental activities of daily living.
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-387Subventions
Organisme : The National Institute of Health Research (NIHR) under the RD-TRC programme and the Wyck Foundation
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Harper PS. Myotonic Dystrophy (3rd ed.). London: W.B. Saunders; 2001.
Hunter A, Tsilfidis C, Mettler G, et al. The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. J Med Genet. 1992;29(11):774-779.
Harley HG, Rundle SA, MacMillan JC, et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet. 1993;52(6):1164-1174.
Mah JK, Korngut L, Fiest KM, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43(1):163-177.
Thornton CA, Wang E, Carrell EM. Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev. 2017;44:135-140.
Gagnon C, Heatwole C, Hébert LJ, et al. Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France, June 8, 2015. J Neuromuscul Dis. 2018;5:523-537.
Hobart JC, Cano SJ, Zajicek JP, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol. 2007;6:1094-1105.
Hermans MC, Faber CG, De Baets MH, de Die-Smulders CE, Merkies IS. Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscul Disord. 2010;20(5):310-318.
Hermans MC, Hoeijmakers JG, Faber CG, Merkies IS. Reconstructing the Rasch-built myotonic dystrophy type 1 activity and participation scale. PLoS ONE. 2015;10(10):e0139944.
Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests (1st ed.). Copenhagen: Danish Institute for Education Research; 1960.
DiPaolo G, Jimenez-Moreno C, Nikolenko N, et al. Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA). J Neurol. 2017;264(4):701-708.
Sedehizadeh S, Brook JD, Maddison P. Body composition and clinical outcome measures in patients with myotonic dystrophy type 1. Neuromuscul Disord. 2017;27(3):286-289.
Okkersen K, Jimenez-Moreno C, Wenninger S, et al. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurol. 2018;17(8):671-680.
Morales F, Couto JM, Higham CF, et al. Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity. Hum Mol Genet. 2012;21:3558-3567.
Gomes-Pereira M, Bidichandani SI, Monckton DG. Analysis of unstable triplet repeats using small-pool polymerase chain reaction. Methods Mol Biol. 2004;277:61-76.
Monckton DG, Wong L-JC, Ashizawa T, Caskey CT. Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses. Hum Mol Genet. 1995;4(1):1-8.
Cumming SA, Jimenez-Moreno C, Okkersen K, et al. Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort. Neurology. 2019;93(10):e995-e1009.
Overend G, Légaré C, Mathieu J, et al. Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes. Hum Mol Genet. 2019;28(13):2245-2254.
Kierkegaard M, Harms-Ringdahl K, Holmqvist LW, Tollbäck A. Functioning and disability in adults with myotonic dystrophy type 1. Disabil Rehabil. 2011;33(19-20):1826-1836.
Van Heugten C, Meuleman S, Hellebrekers D, Kruitwagen-van Reenen E, Visser-Meily J. Participation and the role of neuropsychological functioning in myotonic dystrophy type 1. J Neuromuscul Dis. 2018;5(2):205-214.
Gagnon C, Mathieu J, Noreau L. Life habits in myotonic dystrophy type 1. J Rehabil Med. 2007;39(7):560-566.
Dogan C, De Antonio M, Hamroun D, et al. Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study. PLoS ONE. 2016;11(2):e0148264.
Landfeldt E, Nikolenko N, Jimenez-Moreno C, et al. Disease burden of myotonic dystrophy type 1. J Neurol. 2019;266(4):998-1006.